5-Monobutyl methotrexate

Synonyms: NSC 305986; γ-MBMTX
5-Monobutyl methotrexate (NSC 305986; γ-MBMTX) 是一种二氢叶酸还原酶 (DHFR) 抑制剂和酯酶底物,可被酯酶水解生成 Methotrexate (MS-M11188),其在恒河猴脑脊液中的清除速度慢于血清且与血清蛋白结合率超过 99%,在相同剂量率下可达到与 Methotrexate 相当的脑脊液浓度,并对存在转运缺陷的 Methotrexate 耐药细胞展现出与敏感亲本细胞相当的活性,因此可用于 Methotrexate 耐药肿瘤的相关研究。
产品编号: MS-H09139 CAS No.: 66147-31-7 分子式: C24H30N8O5 分子量: 510.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

5-Monobutyl methotrexate (NSC 305986; γ-MBMTX) 是一种二氢叶酸还原酶 (DHFR) 抑制剂和酯酶底物,可被酯酶水解生成 Methotrexate (MS-M11188),其在恒河猴脑脊液中的清除速度慢于血清且与血清蛋白结合率超过 99%,在相同剂量率下可达到与 Methotrexate 相当的脑脊液浓度,并对存在转运缺陷的 Methotrexate 耐药细胞展现出与敏感亲本细胞相当的活性,因此可用于 Methotrexate 耐药肿瘤的相关研究。

生物实验数据

生物活性 5-Monobutyl methotrexate (NSC 305986; γ-MBMTX) is a dihydrofolate reductase (DHFR) inhibitor and esterase substrate that is hydrolyzed by esterases to generate Methotrexate (MS-M11188), exhibits slower clearance in rhesus monkey cerebrospinal fluid than in serum with over 99% serum protein binding, achieves cerebrospinal fluid concentrations comparable to those of Methotrexate at the same dose rate, and displays activity against Methotrexate-resistant cells with transport defects comparable to that against sensitive parental cells, making it suitable for research on Methotrexate-resistant tumors.
体外研究
(In Vitro)

5-Monobutyl methotrexate (74-290 μM;MeOH 提取液) 在总浓度为 74、130 和 290 μM 时,与恒河猴血清蛋白的结合率 >99%。

体内研究
(In Vivo)

5-Monobutyl methotrexate (γ-MBMTX) (27 mg, 10 g/m2;静脉注射;单次) 在恒河猴体内相对稳定,仅以 Methotrexate (MS-M11188) 为主要代谢产物;5-Monobutyl methotrexate 的血清蛋白结合率 >99%,在等效剂量率下可达到与 Methotrexate 相当的 CSF 浓度,且从 CSF 中的外排速度慢于血清,CSF/血清比值随时间升高。

Animal Model: Macaca mulatta (adult, 10-15 kg, male and female)
Dosage: 27 mg (bolus); 10 g/m2 (1.25-hour infusion); 10 g/m2 (4-hour infusion)
Administration: i.v. (bolus over 1-2 minutes); i.v. (infusion over 1.25 hours); i.v. (infusion over 4 hours)
Result: Accounted for 67%-94% of total serum radioactivity for up to 60 min, with [3H]MTX comprising 4%-13% and only traces of other products after intravenous bolus.
Reached approximately equal proportions with MTX in serum at 2 h after intravenous bolus.
Was the major species in urine over 60 minutes and up to 4 hours, declining from 95% to 54% of total urinary radioactivity, while MTX increased to 31% and other products increased to 15% after intravenous bolus.
Reached free serum level of 1×10-4 M at end of 1.25-h infusion, declining to 7×10-6 M over 5 h.
Peaked at 1.5×10-5 M in CSF after 1.25-h infusion, with CSF/serum ratios increasing from 0.15 at 2 h post-infusion to 1.0 at 5 h post-infusion.
Showed free serum MTX ranging from 1×10-5 M to 4.8×10-6 M over 5 h, with CSF MTX ranging from 4.7×10-6 M to 7.5×10-6 M, and CSF/serum MTX ratios consistently above 0.5 after 1.25-hour infusion.
Remained detectable in serum at 24 hours, with MTX present in CSF at 24 hours (≈4×10-6 M) after 1.25-hour infusion.
Had free serum levels roughly 50% lower than after 1.25-hour infusion at corresponding time points after 4-hour infusion.
Showed CSF levels following a similar lower pattern to serum after 4-hour infusion, with CSF/serum ratios increasing from 0.18 at end of infusion to 1.2 at 3 hours post-infusion.
Was below 1×10-6 M in free serum at 24 hours, while remaining above 4×10-6 M in CSF after 4-hour infusion.
Showed free serum MTX peaking at 5.4×10-4 M at 2 hours post-infusion, with MTX undetectable in CSF (<1×10-6 M) at all time points after 4-hour infusion.

化学信息

分子量 510.55
分子式 C24H30N8O5
CAS No. 66147-31-7
别名 NSC 305986; γ-MBMTX

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础